DE602004022315D1 - Cripto-antagonismus von activin und tgf-b signalisierung - Google Patents

Cripto-antagonismus von activin und tgf-b signalisierung

Info

Publication number
DE602004022315D1
DE602004022315D1 DE602004022315T DE602004022315T DE602004022315D1 DE 602004022315 D1 DE602004022315 D1 DE 602004022315D1 DE 602004022315 T DE602004022315 T DE 602004022315T DE 602004022315 T DE602004022315 T DE 602004022315T DE 602004022315 D1 DE602004022315 D1 DE 602004022315D1
Authority
DE
Germany
Prior art keywords
tgf
activin
signaling
cripto
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004022315T
Other languages
English (en)
Inventor
Wylie Vale
Peter C Gray
Craig Adam Harrison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of DE602004022315D1 publication Critical patent/DE602004022315D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
DE602004022315T 2003-09-15 2004-09-14 Cripto-antagonismus von activin und tgf-b signalisierung Active DE602004022315D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50304603P 2003-09-15 2003-09-15
PCT/US2004/029967 WO2005028433A2 (en) 2003-09-15 2004-09-14 CRIPTO ANTAGONISM OF ACTIVIN AND TGF-β SIGNALING

Publications (1)

Publication Number Publication Date
DE602004022315D1 true DE602004022315D1 (de) 2009-09-10

Family

ID=34375305

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004022315T Active DE602004022315D1 (de) 2003-09-15 2004-09-14 Cripto-antagonismus von activin und tgf-b signalisierung

Country Status (9)

Country Link
US (4) US7820620B2 (de)
EP (2) EP2135952A3 (de)
JP (1) JP5033420B2 (de)
AT (1) ATE437950T1 (de)
AU (1) AU2004274433B2 (de)
CA (1) CA2539116C (de)
DE (1) DE602004022315D1 (de)
DK (1) DK1670511T3 (de)
WO (1) WO2005028433A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
SK14432003A3 (sk) 2001-04-26 2004-07-07 Biogen, Inc. Protilátka špecifická pre Cripto, kompozícia obsahujúca takúto protilátku a jej použitie
WO2005000899A2 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
KR20070100346A (ko) * 2005-01-05 2007-10-10 바이오겐 아이덱 엠에이 인코포레이티드 크립토 결합 분자
US7666423B2 (en) * 2006-07-28 2010-02-23 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
CN101909637B (zh) 2007-11-13 2013-09-18 菲尼克斯生物技术公司 确定用强心苷进行的癌症化疗中的治疗应答概率的方法
EP2350131B1 (de) * 2008-11-07 2017-06-07 Research Development Foundation Zusammensetzungen und methoden zur inhibierung der cripto/grp78-komplexbildung und signalvermittlung
EP2625264B1 (de) 2010-10-08 2022-12-07 Terumo BCT, Inc. Verfahren und systeme für züchtung und ernte von zellen in einem hohlfaser-bioreaktorsystem mit steuerungsbedingungen
WO2012138223A2 (en) 2011-04-05 2012-10-11 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Compounds and methods for altering activin receptor-like kinase signalling
CA2833283A1 (en) 2011-05-02 2012-11-08 Brock University Processes and intermediates in the preparation of morphine analogs via n-demethylation of n-oxides using cyclodehydration reagents
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
CN107428818A (zh) * 2015-01-29 2017-12-01 密西根州立大学校董会 隐藏多肽及其用途
CN114736307A (zh) 2015-04-06 2022-07-12 阿塞勒隆制药公司 TGF-β超家族I型和II型受体异多聚体及其用途
MA53883A (fr) 2015-04-06 2021-08-18 Acceleron Pharma Inc Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3464565A4 (de) 2016-05-25 2020-01-01 Terumo BCT, Inc. Zellexpansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
CA3039573A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Alk4:actriib heteromultimers and uses thereof
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5264557A (en) 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
CA2149441C (en) * 1992-11-17 2004-03-02 Kohei Miyazono Activin receptor-like kinases, proteins having serine threonine kinase domains and their use
CA2215394C (en) * 1995-03-23 2011-04-26 Immunex Corporation Il-17 receptor
US7297478B1 (en) * 2000-09-22 2007-11-20 Large Scale Biology Corporation Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
WO2001073132A1 (en) * 2000-03-27 2001-10-04 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
NZ525380A (en) 2000-09-18 2008-06-30 Biogen Idec Inc Non-fucosylated forms of Cripto and their use as tumor blocking agents
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
WO2003083041A2 (en) 2002-03-22 2003-10-09 Biogen, Inc. Cripto-specific antibodies
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
SK14432003A3 (sk) * 2001-04-26 2004-07-07 Biogen, Inc. Protilátka špecifická pre Cripto, kompozícia obsahujúca takúto protilátku a jej použitie
WO2004083375A2 (en) 2003-03-21 2004-09-30 Gabriella Minchiotti Methods of promoting the differentiation of stem cells

Also Published As

Publication number Publication date
ATE437950T1 (de) 2009-08-15
US20110009319A1 (en) 2011-01-13
US20050208045A1 (en) 2005-09-22
US9546210B2 (en) 2017-01-17
JP5033420B2 (ja) 2012-09-26
JP2007536203A (ja) 2007-12-13
AU2004274433A1 (en) 2005-03-31
EP1670511A2 (de) 2006-06-21
EP2135952A3 (de) 2010-09-29
DK1670511T3 (da) 2009-11-23
WO2005028433A2 (en) 2005-03-31
AU2004274433B2 (en) 2010-08-12
US20120088287A1 (en) 2012-04-12
US20120141469A1 (en) 2012-06-07
CA2539116C (en) 2014-11-18
WO2005028433A3 (en) 2006-01-05
US7820620B2 (en) 2010-10-26
EP2135952A2 (de) 2009-12-23
EP1670511A4 (de) 2008-03-26
CA2539116A1 (en) 2005-03-31
EP1670511B1 (de) 2009-07-29

Similar Documents

Publication Publication Date Title
DE602004022315D1 (de) Cripto-antagonismus von activin und tgf-b signalisierung
IL161830A0 (en) Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
HRP20010573B1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
PA8521501A1 (es) Ligandos para receptores de melanocortina
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
DE60017540D1 (de) Mehr-herzbereiche reizungssystem mit bedingter refraktärer periode
ATE363291T1 (de) Zusammensetzungen, die mit vegf/vegf und angiopoietin/tie rezeptor-funktionen interferieren
DE60040876D1 (de) Medikamentenzuführeinrichtung
PT1401841E (pt) Derivados substituidos de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno como medicamentos para o tratamento da dor
RS53599B1 (en) PIRIDON DERIVATIVES FOR STRESS MODULATION OF ACTIVATED PROTEIN KINASE SYSTEMS
DK1385825T3 (da) Substituerede 2-pyridincyclohexan-1,4-diaminderivater
ATE381943T1 (de) Zellwachstumsinhibition
BR0317866B1 (pt) artigo absorvente tipo calÇa.
DE60005031D1 (de) Partikel mit kontrollierter freisetzungsrate
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
ECSP056057A (es) Compuestos de benzo[1,2,5]tiadiazole
ITTO20000706A0 (it) Apparecchio alimentatore del tipo a nastro trasportatore.
IT1318616B1 (it) Spray scintillante per biancheria.
PT1200400E (pt) Derivados de pirrolidino-2,3,4-trion-3-oxina substituidas com eficacia como antagonistas do receptor nmda
BR0104353A (pt) Taxanos heterosubstituìdos com acetato c7 como agentes antitumor
AP2294A (en) Spiropiperidine derivatives for controlling pests.
NO20003859D0 (no) Bæreinnretning for barn
FR2815332B1 (fr) Devidoir suspendu, notamment pour cultures
HRP20080179T3 (en) Novel imidazopyridine compound ii with therapeutic effect
ZA200408029B (en) Novel 1,3,5-triazine derivatives as ligands for human adenosine-A3 receptors.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition